Total Payments
$11,156
2024 Payments
$8,454
Companies
5
Transactions
14
Medicare Patients
412
Medicare Billing
$25,412
Payment Breakdown by Category
Consulting$8,509 (76.3%)
Research$1,359 (12.2%)
Other$1,250 (11.2%)
Food & Beverage$37.34 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,509 | 3 | 76.3% |
| Unspecified | $1,359 | 4 | 12.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,250 | 4 | 11.2% |
| Food and Beverage | $37.34 | 3 | 0.3% |
Payments by Type
General
$9,796
10 transactions
Research
$1,359
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $4,598 | 6 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,855 | 5 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,685 | 1 | $0 (2021) |
| Acclarent, Inc | $14.17 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,454 | 11 | GENZYME CORPORATION ($4,598) |
| 2021 | $2,702 | 3 | AstraZeneca Pharmaceuticals LP ($2,685) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $3,328.00 | General |
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,496.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/27/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $500.00 | General |
| Category: Immunology | ||||||
| 06/15/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 05/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $286.55 | Research |
| Study: ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 04/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $250.00 | General |
| Category: Immunology | ||||||
| 04/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $393.10 | Research |
| Study: ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $393.10 | Research |
| Study: ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 01/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Immunology | ||||||
| 01/01/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | — | In-kind items and services | $286.55 | Research |
| Study: ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) • Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 06/25/2021 | Forte Bio-Pharma LLC | PROLATE (Drug), NALOCET, PROLATE | Food and Beverage | In-kind items and services | $2.81 | General |
| Category: Pain | ||||||
| 05/11/2021 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,685.00 | General |
| Category: Respiratory | ||||||
| 03/16/2021 | Acclarent, Inc | Acclarent Aera (Device) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Rhinology Otology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | Regeneron Pharmaceuticals, Inc. | $1,359 | 4 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 90 | 131 | $21,670 | $5,694 |
| 2022 | 4 | 91 | 136 | $22,392 | $6,027 |
| 2021 | 6 | 128 | 188 | $33,097 | $8,432 |
| 2020 | 4 | 103 | 140 | $22,090 | $5,259 |
Total Patients
412
Total Services
595
Medicare Billing
$25,412
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 30 | 45 | $6,300 | $2,159 | 34.3% |
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2023 | 22 | 39 | $9,360 | $1,788 | 19.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 20 | 20 | $4,120 | $1,030 | 25.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 18 | 27 | $1,890 | $716.30 | 37.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 61 | $8,540 | $2,839 | 33.2% |
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2022 | 21 | 37 | $8,880 | $1,606 | 18.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 17 | 17 | $3,502 | $1,049 | 30.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 17 | 21 | $1,470 | $532.84 | 36.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 36 | 56 | $7,840 | $2,747 | 35.0% |
| 31231 | Diagnostic examination of nasal passages using an endoscope | Office | 2021 | 20 | 48 | $11,520 | $2,097 | 18.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 20 | 25 | $5,375 | $1,569 | 29.2% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 22 | 22 | $4,532 | $1,153 | 25.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 17 | 21 | $1,470 | $563.80 | 38.4% |
| 69210 | Removal of impact ear wax, one ear | Office | 2021 | 13 | 16 | $2,360 | $302.26 | 12.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 48 | 70 | $9,394 | $2,489 | 26.5% |
| 31231 | Diagnostic examination of nasal passages using an endoscope | Office | 2020 | 19 | 33 | $7,138 | $1,457 | 20.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 23 | 23 | $4,546 | $1,111 | 24.4% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 13 | 14 | $1,012 | $202.79 | 20.0% |
About Dr. James Mims, MD
Dr. James Mims, MD is a Otolaryngology healthcare provider based in Winston Salem, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1194709576.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Mims, MD has received a total of $11,156 in payments from pharmaceutical and medical device companies, with $8,454 received in 2024. These payments were reported across 14 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($8,509).
As a Medicare-enrolled provider, Mims has provided services to 412 Medicare beneficiaries, totaling 595 services with total Medicare billing of $25,412. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Otolaryngology
- Location Winston Salem, NC
- Active Since 11/30/2005
- Last Updated 08/14/2019
- Taxonomy Code 207Y00000X
- Entity Type Individual
- NPI Number 1194709576
Products in Payments
- DUPIXENT (Biological) $5,126
- FASENRA (Biological) $2,685
- Acclarent Aera (Device) $14.17
- PROLATE (Drug) $2.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Otolaryngology Doctors in Winston Salem
William Scurry, M.d, M.D
Otolaryngology — Payments: $139,456
Otolaryngology $139,456
Adam Campbell, Md, MD
Otolaryngology — Payments: $39,453
Otolaryngology $39,453
Mr. John Britt, Md, MD
Otolaryngology — Payments: $4,292
Otolaryngology $4,292
Mr. Stephen Harper, Md, MD
Otolaryngology — Payments: $4,069
Otolaryngology $4,069
Mr. William Mcguirt, Md, MD
Otolaryngology — Payments: $3,486
Otolaryngology $3,486
Mr. Ronald Shealy, Md, MD
Otolaryngology — Payments: $2,344
Otolaryngology $2,344